Summary of Conference Call on Interventional Valves Industry Overview - The heart valve market is experiencing a slowdown in growth, expected to maintain around 20% growth due to market maturity, medical cost control, and price competition within the industry [1][2] - Major brands in the market include Peijia, Qiming, Jintong, and Jianshi, with Jianshi focusing on cash valves [1] - The expected implantation volume for interventional valves in the first half of 2025 is approximately 21,000 cases, with a growth rate of about 20% [2] Key Insights - The market has transitioned from a high-growth phase (40-50% from 2019 to 2022) to a more stable growth phase, with current growth seen as satisfactory [2] - Factors contributing to the slowdown include the market reaching its initial explosive growth phase, economic conditions leading to medical cost control, and increased price competition among manufacturers [2] - The expected price range for heart valves post-collective procurement is projected to drop to between 120,000 to 150,000 yuan, which is about 60-70% of the original factory price [1][8] Pricing and Subsidies - The lowest market price for Lepu's new balloon-expandable valve is 100,000 yuan, while the listed price in Guangzhou is around 158,000 to 160,000 yuan, serving as a reference for price reductions in other provinces [1][7] - Companies like Qiming, Peijia, and Xintong are providing subsidies ranging from 30,000 to 50,000 yuan in central and western regions, although these amounts have decreased compared to previous years [5][6] Market Dynamics - The current market structure is not expected to change significantly in the short term. New entrants must either offer lower prices to gain access or enhance clinical services to improve hospital recognition [9] - The collective procurement policy is anticipated to have a moderate impact on pricing, with potential participation from multiple provinces [4] Product Performance - The implantation volume for Jianshi's cash valves in the first half of 2025 is expected to be around 1,600 cases, while new entrants like Lepu and Shanghai Niupai have seen very low implantation volumes [3] - Self-expanding valves are more widely used, accounting for 95% of implantation volumes, while balloon-expandable valves are noted for their precision and lower complication rates [11] Future Outlook - The domestic electrophysiology market has seen a slowdown in growth, with an expected completion of 550,000 electrophysiology procedures in 2025, but the growth rate is expected to decline further post-2023 due to the saturation of suitable patient populations [27][29] - The development of one-stop atrial fibrillation ablation combined with left atrial appendage closure procedures is promising, although it faces challenges due to payment system limitations [30] Conclusion - The heart valve market is stabilizing with moderate growth expectations, influenced by pricing strategies, competitive dynamics, and regulatory changes. The focus for companies will be on maintaining market share through innovation and effective pricing strategies while navigating the challenges posed by collective procurement policies and market saturation.

Summary of the Conference Call on Electrophysiology Industry Overview - The electrophysiology (EP) industry in China is experiencing continuous growth, with a 10% increase in procedures in the first half of the year, and an expected nationwide growth of 10%-15% due to the adoption of new catheter ablation technologies like pulsed field ablation (PFA) and accelerated domestic substitution [2][3][4] - The patient base for atrial fibrillation (AF) is substantial, estimated at 14-18 million, with increasing incidence due to aging, although the penetration rate of catheter ablation remains low [2][4] Key Insights - **Procedure Growth**: The EP procedures are a highlight in the cardiovascular intervention field, with a 10% growth noted in a major center, and a higher national growth rate anticipated due to the increasing adoption of independent EP teams and local anesthesia techniques [3][4] - **Technology Trends**: - Cryoablation technology is being phased out, while radiofrequency ablation remains dominant. However, PFA is rapidly gaining traction due to its lower technical difficulty and higher safety profile [2][3][7] - In a specific center, radiofrequency ablation accounts for 60%-70% of procedures, while PFA represents 30%-40%, with expectations for PFA's share to increase further [7] - **Market Share**: In the thermal ablation market, Johnson & Johnson holds over 50% market share, Abbott has 30%-40%, and domestic brands have a smaller share. In the AF thermal ablation sector, Johnson & Johnson's market share exceeds 75% [2][9] Patient Treatment Dynamics - **Patient Willingness**: Paroxysmal AF patients typically try medication first, while persistent AF patients are more inclined to opt for catheter ablation due to poor medication efficacy [5][6] - **Success Rates**: Catheter ablation for AF has a high success rate of over 90%, but the recurrence rate is significant, especially for persistent AF [4][6] Competitive Landscape - **Domestic vs. International Brands**: In the PFA era, domestic brands like Jinjiang and Huitai are gaining market share due to their ability to perform procedures under local anesthesia, contrasting with foreign brands that rely on general anesthesia [10][11] - **Emerging Technologies**: The development of nanosecond PSA technology aims to reduce pain and anesthesia needs, although it is still in preclinical stages [15] Future Outlook - **Market Dynamics**: The competitive landscape is shifting, with foreign manufacturers like Abbott lagging behind in innovation. Domestic brands with robust 3D systems are expected to emerge as key players [26] - **Price Trends**: The overall trend in medical pricing is expected to become more affordable, although specific pricing for PFA terminal products remains undisclosed [27][28] Regulatory and Guideline Changes - **Clinical Guidelines**: The U.S. has updated its guidelines to position electrophysiology as a first-line treatment, which is expected to influence domestic guidelines in China [30] Additional Considerations - **One-stop Surgery**: The concept of one-stop surgeries combining electrophysiology and left atrial appendage closure is gaining traction, although it presents challenges in terms of cost and reimbursement [21][23] This summary encapsulates the key points from the conference call regarding the electrophysiology industry, highlighting growth trends, technological advancements, patient treatment dynamics, competitive landscape, future outlook, and regulatory changes.